5J-4 is a potent CRAC inhibitor. 5J-4 decreases the numbers of infiltrated mononuclear cell into the CNS, and significantly decreases the population of infiltrated CD4+ population. 5J-4 reduces the symptoms and delayed the onset of EAE (experimental autoimmune encephalomyelitis) in mouse model of inflammation. In Vivo 5J-4 reduces the production of IL-17 and decreases the expression of RORα and RORγt . 5J-4 (2 mg/kg; i.p.; every alternate day for 30 days) reduces the symptoms and delayed the onset of EAE . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 mice (MOG35-55 peptide-immunized mice) Dosage: 2 m/kg Administration: I.p., every alternate day for 30 days Result: Dramatically reduced the symptoms and delayed the onset of EAE and decreased the numbers of infiltrated mononuclear cell into the CNS, and significantly decreased the population of infiltrated CD4+ population. Form:Powder